Facilitating the New Normal
While many of the restrictions we have faced in the last two years have been lifted to reconstitute what we remember to be normal, we are...
top of page
BEYOND LIFE-CHANGING
PHARMACEUTICAL SOLUTIONS
OLTRE BIOMEDICAL
PRESENTS
CAVALTINIB™
OUR MISSION
OLTRE BIOMEDICAL Inc. was established with the expressed purpose of funding and pursuing clinical trials in Canada and the USA for its promising drug treatment for respiratory diseases.
In 2022, the more immediate interest and focus will be on the urgently needed treatment of COVID-19 patients in distress.
EXPLORING CAVALTINIB™
Cavaltinib™ has been shown in published research to inhibit the cytokines responsible for the ‘cytokine storm’ phenomenon at a central upstream mechanism that reduces the transcription (production) of many causal cytokines that drive these diseased states.
This work has subsequently led to approval by Health Canada for a clinical trial for what appears to be a good COVID-19 drug candidate.
A MESSAGE FROM THE CEO
bottom of page